UA87269C2 - Функционально восстановленная вирусная мембрана, содержащая адъювант, способ получения восстановленной вирусной мембраны и фармацевтическая композиция, содержащая восстановленную вирусную мембрану - Google Patents

Функционально восстановленная вирусная мембрана, содержащая адъювант, способ получения восстановленной вирусной мембраны и фармацевтическая композиция, содержащая восстановленную вирусную мембрану

Info

Publication number
UA87269C2
UA87269C2 UAA200512191A UAA200512191A UA87269C2 UA 87269 C2 UA87269 C2 UA 87269C2 UA A200512191 A UAA200512191 A UA A200512191A UA A200512191 A UAA200512191 A UA A200512191A UA 87269 C2 UA87269 C2 UA 87269C2
Authority
UA
Ukraine
Prior art keywords
viral membrane
reconstructed viral
reconstructed
fusion
viral
Prior art date
Application number
UAA200512191A
Other languages
English (en)
Ukrainian (uk)
Inventor
Антониус Йоханнес Хендрикус Стегманн
Ян Кристиан Вилсхут
Беркум Йоханнес Хенрикус Герардус ван
Original Assignee
Бестевил Холдинг Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бестевил Холдинг Б.В. filed Critical Бестевил Холдинг Б.В.
Publication of UA87269C2 publication Critical patent/UA87269C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение относится к восстановленной вирусной мембране, двойной липидный слой которой содержит слитный вирусный протеин, амфифильный адъювант и необязательно дополнительный антиген. При этом двойной липидный слой имеет композицию липидов, совместимую с индуцируемым слитным протеином слиянием вирусной мембраны с клеточной мембраной. Последняя может сливаться с вирусом, из которого получен указанный слитный протеин. Слитный протеин и амфифильный адъювант взаимодействуют с гидрофобной внутренней частью двойного липидного слоя. При этом и слитный протеин, и амфифильный адъювант и необязательный дополнительный антиген не связаны ковалентно. Также, изобретение относится к способу получения восстановленной вирусной мембраны и фармацевтической композиции, которая содержит восстановленную вирусную мембрану.
UAA200512191A 2003-06-19 2004-06-18 Функционально восстановленная вирусная мембрана, содержащая адъювант, способ получения восстановленной вирусной мембраны и фармацевтическая композиция, содержащая восстановленную вирусную мембрану UA87269C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL0300450 2003-06-19

Publications (1)

Publication Number Publication Date
UA87269C2 true UA87269C2 (ru) 2009-07-10

Family

ID=33550371

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200512191A UA87269C2 (ru) 2003-06-19 2004-06-18 Функционально восстановленная вирусная мембрана, содержащая адъювант, способ получения восстановленной вирусной мембраны и фармацевтическая композиция, содержащая восстановленную вирусную мембрану

Country Status (20)

Country Link
US (1) US7618641B2 (ru)
EP (2) EP1633395B1 (ru)
JP (1) JP4685005B2 (ru)
KR (1) KR101225199B1 (ru)
CN (1) CN100556454C (ru)
AR (1) AR056245A1 (ru)
AU (1) AU2004246974B2 (ru)
BR (1) BRPI0411519A (ru)
CA (1) CA2527735C (ru)
DK (2) DK1633395T3 (ru)
ES (2) ES2536689T3 (ru)
IL (1) IL172584A (ru)
MX (1) MXPA05013929A (ru)
NO (1) NO20055934L (ru)
PL (2) PL1633395T3 (ru)
RU (1) RU2348428C2 (ru)
TW (1) TWI329130B (ru)
UA (1) UA87269C2 (ru)
WO (1) WO2004110486A1 (ru)
ZA (1) ZA200509907B (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006206851B2 (en) 2005-01-18 2010-12-16 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Mycobacteria with mannose cap-deficient lipoarabinomannan
AR059972A1 (es) * 2006-03-22 2008-05-14 Solvay Pharm Bv Administracion intranasal o inhalacional de virosomas
US8535683B2 (en) 2006-03-22 2013-09-17 Abbott Biologicals B.V. Intranasal or inhalational administration of virosomes
TWI397419B (zh) * 2006-03-22 2013-06-01 Abbott Biologicals Bv 病毒顆粒的鼻內或吸入給藥
US8916164B2 (en) * 2007-08-29 2014-12-23 Abivax Methods of enhancing adjuvaticity of vaccine compositions
EP2058002A1 (en) 2007-10-31 2009-05-13 Bestewil Holding B.V. Reconstituted respiratory syncytial virus membranes and use as respiratory syncytial virus vaccine
MX2011007703A (es) 2009-02-06 2011-09-28 Mymetics Corp Antigenos gp41 novedosos.
EP2393509A1 (en) 2009-02-06 2011-12-14 Mymetics Corporation Splitting gp41
EA023725B1 (ru) * 2010-03-23 2016-07-29 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
WO2011128720A1 (en) 2010-04-14 2011-10-20 Mymetics Corporation Trans-activator of transcription protein
CN103179977B (zh) 2010-08-27 2016-10-26 潘塔希生物科学股份有限公司 治疗前列腺癌的免疫治疗方法
CN103154251A (zh) * 2010-09-30 2013-06-12 佛兰瓦克斯有限责任公司 病毒体颗粒的生产
EP3016679B1 (en) 2013-07-02 2019-03-27 Janssen Vaccines & Prevention B.V. Method for preparing virosomes
CA2960948C (en) * 2014-09-12 2023-04-04 Bestewil Holding B.V. Methods for providing adjuvanted virosomes and adjuvanted virosomes obtainable thereby
WO2016039620A2 (en) 2014-09-12 2016-03-17 Bestewil Holding B.V. Respiratory syncytial virus virosomes
WO2016080830A2 (en) 2014-11-18 2016-05-26 Pantarhei Bioscience B.V. Immunotherapeutic method for treating pancreatic cancer
EP3703734A1 (en) 2017-10-31 2020-09-09 Pantarhei Bioscience B.V. Immunotherapeutic methods for treating and/or preventing lung cancer
US20210317165A1 (en) 2018-09-03 2021-10-14 Laboratoire Hra-Pharma Zp3 fragments in immunotherapy of ovarian cancer
US11523988B2 (en) 2018-11-29 2022-12-13 Catalent U.K. Swindon Zydis Limited Oral dispersible vaccine comprising virosomes
WO2020121062A1 (en) 2018-12-12 2020-06-18 Anergis S.A. Methods of improving efficacy of allergy vaccines
WO2021207303A1 (en) * 2020-04-07 2021-10-14 Alsatech, Inc. Immune stimulation against coronavirus infections
WO2023066923A1 (en) 2021-10-19 2023-04-27 Rahman Nafis Male contraception
WO2023237726A1 (en) 2022-06-10 2023-12-14 Pantarhei Oncology B.V. An intracellular tumor-specific variant of human zona pellucida glycoprotein 3 and nucleic acids coding therefor for use in the treatment of cancer
WO2024088138A1 (zh) * 2022-10-25 2024-05-02 宁波明亦生物科技有限公司 质膜透化灭活口服疫苗

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4542212A (en) 1975-10-14 1985-09-17 Institut Pasteur Phosphorylated 3-glyceryl-esters of glucose
JPS5929931B2 (ja) * 1980-12-09 1984-07-24 オムロン株式会社 安全スイツチ
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
JPH0688911B2 (ja) 1985-06-06 1994-11-09 国立予防衛生研究所長 インフルエンザワクチン及びその製造方法
ATE71303T1 (de) 1986-01-14 1992-01-15 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
NZ224422A (en) 1987-05-05 1990-11-27 Molecular Eng Ass Composition adapted for intranasal immunisation against viral infection comprising a glycoprotein complexed with a lipid
NZ240369A (en) 1990-10-30 1993-09-27 Daiichi Seiyaku Co Muramyl dipeptide derivatives and vaccine compositions
US5879685A (en) 1991-05-08 1999-03-09 Schweiz, Serum- & Impfinstitut Bern Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
ES2135406T3 (es) * 1991-05-08 1999-11-01 Schweiz Serum & Impfinst Virosomas de la influenza reconstituidos inmunoestimulantes e inmunopotencializadores y vacunas que los contienen.
US20030113347A1 (en) 1991-05-08 2003-06-19 Schweiz. Serum- & Impfinstitut Bern Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
US5936076A (en) * 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
DE69730218D1 (de) * 1996-04-11 2004-09-16 Univ British Columbia Fusogene liposomen
ES2267724T3 (es) 2000-02-15 2007-03-16 Id Biomedical Corporation Of Quebec Vacuna antigripal basada en proteosomas.
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
US20030092145A1 (en) * 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
DE60335742D1 (de) * 2002-11-20 2011-02-24 Bestewil Holding Bv Zusammensetzungen mit antigen-komplexen,verfahren zu ihrer herstellung und verfahren zur verwendung derantigen-komplexe zur vakzinierung
US7491395B2 (en) * 2002-11-20 2009-02-17 Bestewil Holding B.V. Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination

Also Published As

Publication number Publication date
AR056245A1 (es) 2007-10-03
KR20060030047A (ko) 2006-04-07
JP4685005B2 (ja) 2011-05-18
EP1633395A1 (en) 2006-03-15
EP2368576A2 (en) 2011-09-28
TWI329130B (en) 2010-08-21
EP2368576B1 (en) 2015-02-25
CA2527735A1 (en) 2004-12-23
IL172584A0 (en) 2006-04-10
WO2004110486A1 (en) 2004-12-23
AU2004246974B2 (en) 2010-05-06
DK2368576T3 (en) 2015-05-18
CN1805754A (zh) 2006-07-19
AU2004246974A1 (en) 2004-12-23
EP2368576A3 (en) 2012-03-28
DK1633395T3 (da) 2012-10-29
EP1633395B1 (en) 2012-08-01
US20060193873A1 (en) 2006-08-31
BRPI0411519A (pt) 2006-08-01
KR101225199B1 (ko) 2013-01-23
US7618641B2 (en) 2009-11-17
ES2390454T3 (es) 2012-11-13
ES2536689T3 (es) 2015-05-27
NO20055934L (no) 2006-03-20
RU2006101394A (ru) 2006-06-10
JP2006527598A (ja) 2006-12-07
IL172584A (en) 2010-11-30
TW200510538A (en) 2005-03-16
ZA200509907B (en) 2006-11-29
PL2368576T3 (pl) 2015-12-31
PL1633395T3 (pl) 2012-12-31
MXPA05013929A (es) 2006-03-08
CN100556454C (zh) 2009-11-04
RU2348428C2 (ru) 2009-03-10
CA2527735C (en) 2014-12-16

Similar Documents

Publication Publication Date Title
UA87269C2 (ru) Функционально восстановленная вирусная мембрана, содержащая адъювант, способ получения восстановленной вирусной мембраны и фармацевтическая композиция, содержащая восстановленную вирусную мембрану
Itel et al. Dynamics of membrane proteins within synthetic polymer membranes with large hydrophobic mismatch
WO2010018003A3 (en) Carrier system for biological agents containing organosilicon compounds and uses thereof
SE9403245D0 (sv) Improvements relating to bilayer lipid membranes
WO2000039302A3 (en) Improved expression of hiv polypeptides and production of virus-like particles
WO2006033679A3 (en) Self-assembling nanoparticle drug delivery system
WO2003029403A3 (en) Targeting proteins to cells expressing mannose receptors via expression in insect cells
EA200601753A1 (ru) Синтетические "мембранные якори"
PL1948817T3 (pl) Transkrypcja i translacja białek membranowych bez udziału komórek w związanych z powierzchnią planarnych warstwach lipidowych
WO2006110350A3 (en) Method of fabricating lipid bilayer membranes on solid supports
ATE544470T1 (de) Immuntherapeutische methoden und zusammensetzungen
ATE332914T1 (de) Mimotope und antimimotope des menschlichen plättchen-glykoproteins ib/ix
JP5069920B2 (ja) マンノース６−リン酸−ポリエチレングリコール結合体
CA2379346A1 (en) Conjugate for mediating cell-specific, compartment-specific or membrane-specific transport of active substances
WO2002056831A3 (en) Immunogenic proteoliposomes, and uses thereof
WO2000066173A3 (en) Targeting of infectious agents bearing host cell proteins
Trommeshauser et al. Interaction of a basic amphipathic peptide from the carboxyterminal part of the HIV envelope protein gp41 with negatively charged lipid surfaces
WO2007122756A1 (ja) オリゴ糖を表面に有するリポソームを含むアレルギー治療剤
Licen et al. Artificial anion transporters in bilayer membranes
Jelinek Membranes: From Biological Functions to Therapeutic Applications
WO2003077838A3 (en) Hiv-1 envelope glycoproteins stabilized by flexible linkers as potent entry inhibitors and immunogens
DE60219601D1 (de) Durch liposome vermittelte dna verabreichung
Muñoz et al. The covalent coupling of HAV-VP3 (110–121) synthetic peptide to liposomes: physicochemical studies
TW476761B (en) A process for preparing the derivative of a dipeptide and (R)-Α-hydroxy benzoic acid ester and pharmaceutically acceptable salts thereof
Shi et al. Single Molecule Diffusion of Phosphatidylinositol Bisphosphate (PIP2) Lipids on Asymmetric Lipid Bilayers under the Influence of Polycationic Macromolecules